礼来(LLY. US)拿到了中国口服小分子GLP-1减肥药赛道的第一张“入场券”。 11月12日,国家药监局官网显示,礼来的口服小分子GLP-1受体激动剂奥氟格列隆钙片(商品名:穆优达)获批上市,适用于在控制饮食和增加运动基础上,用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。 奥氟格列隆由此成为国内首个获批用于成人体重管理的口服GLP-1受体激动剂。 过去几年间,大众对GLP-1...
Source Link礼来(LLY. US)拿到了中国口服小分子GLP-1减肥药赛道的第一张“入场券”。 11月12日,国家药监局官网显示,礼来的口服小分子GLP-1受体激动剂奥氟格列隆钙片(商品名:穆优达)获批上市,适用于在控制饮食和增加运动基础上,用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。 奥氟格列隆由此成为国内首个获批用于成人体重管理的口服GLP-1受体激动剂。 过去几年间,大众对GLP-1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.